Yahoo · Sep 4, 2026
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MI
NASDAQ · MIRM
Mirum Pharmaceuticals, Inc.
Healthcare · Biotechnology
$100.61
Up+$2.31 (+2.35%)
Updated Sep 11, 2026, 8:19 AM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.25B
- P/E ratio
- -80.38
- Dividend yield
- 0.00%
- 52-week range
- $84.33 – $130.00
- Volume
- 587.04K
- Avg. volume
- 656.21K
Price performance
MIRM price history
1M range · 20 trading sessions · Daily adjusted prices
MIRM closed at $100.61 after 20 trading sessions, up 1.86% for the selected period.
- Last close
- $100.61
- Period change
- +1.86%
- Period low
- $96.31
- Period high
- $102.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $98.30 | $101.1799 | $97.48 | $100.61 | 587.04K |
| Sep 9, 2026 | $98.02 | $101.50 | $97.01 | $98.30 | 521.76K |
| Sep 8, 2026 | $98.49 | $101.8275 | $97.645 | $99.53 | 638.47K |
| Sep 4, 2026 | $99.08 | $101.99 | $99.08 | $100.90 | 350.96K |
| Sep 3, 2026 | $101.56 | $101.7299 | $99.055 | $100.63 | 453.04K |
| Sep 2, 2026 | $98.95 | $101.00 | $97.66 | $99.83 | 495.63K |
| Sep 1, 2026 | $97.84 | $99.69 | $97.47 | $98.34 | 398.38K |
| Aug 31, 2026 | $97.46 | $98.40 | $95.605 | $98.05 | 419.81K |
| Aug 28, 2026 | $99.43 | $100.06 | $96.545 | $97.46 | 426.51K |
| Aug 27, 2026 | $97.94 | $100.095 | $96.01 | $99.75 | 402.12K |
| Aug 26, 2026 | $97.95 | $98.80 | $95.00 | $98.51 | 571.06K |
| Aug 25, 2026 | $98.50 | $100.20 | $95.00 | $98.08 | 472.29K |
| Aug 24, 2026 | $96.31 | $97.85 | $95.49 | $96.72 | 367.57K |
| Aug 21, 2026 | $97.65 | $97.89 | $95.24 | $96.31 | 731.68K |
| Aug 20, 2026 | $100.73 | $101.96 | $96.98 | $97.07 | 352.68K |
| Aug 19, 2026 | $102.50 | $104.66 | $101.54 | $102.24 | 556.27K |
| Aug 18, 2026 | $99.50 | $101.26 | $99.00 | $100.87 | 518.11K |
| Aug 17, 2026 | $99.93 | $101.43 | $99.23 | $99.83 | 407.63K |
| Aug 14, 2026 | $98.03 | $101.31 | $96.73 | $100.64 | 503.79K |
| Aug 13, 2026 | $99.23 | $100.48 | $98.50 | $98.77 | 734.95K |
Latest MIRM news
The latest Smart Investors Daily articles mentioning MIRM.
Stock researchCompany · Overview
MIRM research
Overview
Company profile and research snapshot.
Company profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $98.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | TD Cowen | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif., September 02, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Benzinga · Aug 27, 2026
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Yahoo · Aug 24, 2026
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
Recently published Liver Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, liver cirrhosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
